MetaCap

Celularity (CELU) vs Quoin Pharmaceuticals (QNRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Celularity (CELU) has outperformed Quoin Pharmaceuticals (QNRX) over the past year, losing 73.5% versus a loss of 82.1%. Over five years, CELU leads with a -99.3% price change compared with -100.0% for QNRX. Quoin Pharmaceuticals is the larger company by market cap ($15.8 million vs $15.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CELU-73.54%QNRX-82.07%
+27%-30%-87%
Nov 21, 20251 yearNov 20, 2026
CELU-99.34%QNRX-99.99%
+84%-13%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CELU versus QNRX key metrics
MetricCELUQNRX
Share price$0.463$3.28
Market cap$15.02M$15.76M
1-day change-1.05%-2.35%
YTD return-58.29%-77.27%
1-year return-73.54%-82.07%
5-year return-99.31%-99.99%
P/E ratio (TTM)—7.45
EPS (TTM)$-1.69$0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$26.55M—
Revenue growth (YoY)-51.03%—
Net income (latest FY)$-91.72M$-15.80M
Gross margin24.39%—
Operating margin-230.92%—
Net margin-345.45%—
52-week high$2.55$23.50
52-week low$0.42$3.18
Distance from 52-week high-81.84%-86.04%
Analyst consensus—none
Avg. price target upside—+565.55%
Average volume3.95M541.26K
Shares outstanding32.45M4.80M
Employees1154
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Celularity

CELU stock →

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.

Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees

About Quoin Pharmaceuticals

QNRX stock →

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

CELU vs QNRX FAQ

Which is bigger, Celularity or Quoin Pharmaceuticals?

Quoin Pharmaceuticals (QNRX) is larger, with a market capitalization of $15.76M compared with $15.02M for Celularity (CELU).

Which stock has performed better over the past year, CELU or QNRX?

CELU returned -73.54% over the past 12 months, compared with -82.07% for QNRX (price return, excluding dividends). Past performance does not predict future results.

Are Celularity and Quoin Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons